Navigation Links
Proton pump inhibitors increase risk of heart attacks for patients on common cardiac drug

Patients taking the common cardiac drug clopidogrel following a heart attack are at a significantly higher risk of a recurrence if they are also taking widely used acid-lowering medications called proton pump inhibitors, a new study published online in CMAJ has found (

The study, conducted over 6 years in thousands of heart attack patients aged 66 years and older, found a significantly increased risk of readmission for heart attacks if patients were taking one of several proton pump inhibitors, including omeprazole, lansoprazole, or rabeprazole. The investigators found no such association with the proton pump inhibitor pantoprazole or with other acid-lowering medications called H2 receptor antagonists.

Previous research indicates that proton pump inhibitors other than pantoprazole can block the liver's ability to convert clopidogrel to its active form,a critical step required for clopidogrel's anti-platelet effect.

These findings could have significant public health implications. Proton pump inhibitors (PPIs) are among the most commonly prescribed drugs in the world, with more than 12.4 million prescriptions in Canada alone in 2004. Clopidogrel is the second-highest selling drug in the world, with annual sales totalling $7.3 billion.

Recent guidelines from the American Heart Association, the American College of Gastroenterology, and the American College of Cardiology recommend proton pump inhibitor therapy for many patients following a heart attack to prevent bleeding from the stomach, including all patients aged 60 years or older receiving ASA. Because clopidogrel and ASA are often prescribed together following a heart attack, it is probable that millions of patients worldwide will take a proton pump inhibitor with clopidogrel.

"Depending on the exposure to these drugs following a heart attack, we estimate that 5% to 15% of early readmissions for myocardial infarction among patients taking clopidogrel could be the result of this drug interaction," writes Dr. David Juurlink, Head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre and lead author of the study, which was conducted at the Institute for Clinical Evaluative Sciences (ICES). "These findings highlight a widely unappreciated, extremely common and completely avoidable drug interaction in a population of patient at very high risk of reinfarction."

"Our findings suggest that indiscriminate treatment with a proton pump inhibitor could result in thousands of additional cases of recurrent myocardial infarction each year, all of which could be avoided simply by selectively prescribing pantoprazole in patients receiving clopidogrel who require treatment with a proton pump inhibitor," write the authors.


Contact: Kim Barnhardt
613-731-8610 x2224
Canadian Medical Association Journal

Related medicine news :

1. Historic Agreement Reached to More Expertly and Efficiently Expand Proton Therapy Worldwide
2. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
3. Loma Linda University to Dedicate Proton Treatment Center to Cancer Therapy Pioneer James M. Slater, M.D.
4. Eclipse(TM) Proton Scanning Algorithm from Varian Medical Systems Receives FDA Clearance
5. Proton-powered pooping
6. Wyeth Announces Launch of Own Generic Version of PROTONIX
7. Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
8. Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment
9. Gastric juice for diagnosis of H. pylori infection in patients on proton pump inhibitors
10. Varian Medical Systems to Develop Interface Between the ARIA(TM) Oncology Information System and the Monarch250(TM) Proton Radiotherapy System From Still River Systems
11. LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug
Post Your Comments:
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: